FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W60323329> ?p ?o ?g. }

• W60323329 endingPage "262" @default.
• W60323329 startingPage "241" @default.
• W60323329 abstract "mTOR (mammalian Target of Rapamycin) is the hub of the phosphoinositide 3-Kinase (PI3-K)→Akt→mTOR pathway, which is one of the most commonly mutated pathways in cancer. PI3-Ks and mTOR are related kinases which share an evolutionarily related kinase domain, although the former is a lipid kinase and the latter is a protein kinase. As a result of their similar ATP sites, the prototypical PI3-K inhibitors LY294002 and wortmannin inhibit both kinases, although the compounds have been primarily thought of as inhibitors of PI3-Ks. The widespread use of these reagents to understand PI3-K signaling and the likelihood that many of their effects are confounded by dual inhibition of PI3-K and mTOR make it essential to develop selective mTOR inhibitors in part to understand the unique cellular effects of inhibition of this key downstream component in the growth factor pathway. Rapamycin has historically provided a means for selective mTOR inhibition, yet it is not a typical ATP competitive inhibitor, making its effects difficult to reconcile with LY294002 and wortmannin. Several groups have recently reported pharmacological agents which inhibit mTOR but not PI3-K, providing a new pharmacological approach to selective mTOR inhibition. The TOR kinase domain inhibitors of mTOR have been termed TORKinibs to distinguish their mode of action from rapamycin and its analogs (rapalogs). These inhibitors bind to the ATP binding site of the kinase domain of mTOR and as a result inhibit both mTOR complexes, TORC1 (rapamycin sensitive) and TORC2 (rapamycin resistant). These molecules have allowed a reinvestigation of mTOR and in particular a reinvestigation of the mechanistic basis for incomplete proliferative arrest of cells by Rapamycin. A consensus has quickly emerged from the study of various TORKinibs that Rapamycin is ineffective at blocking cell proliferation because it only partially inhibits the activity of mTORC1. The profound anti-proliferative effect of TORKinibs suggests that as the molecules enter the clinic they may be successful in the treatment of cancers where rapamycin has failed." @default.
• W60323329 created "2016-06-24" @default.
• W60323329 creator A5067213450 @default.
• W60323329 creator A5079376363 @default.
• W60323329 date "2010-01-01" @default.
• W60323329 modified "2023-09-26" @default.
• W60323329 title "New Inhibitors of the PI3K-Akt-mTOR Pathway: Insights into mTOR Signaling from a New Generation of Tor Kinase Domain Inhibitors (TORKinibs)" @default.
• W60323329 cites W1529396499 @default.
• W60323329 cites W1585385265 @default.
• W60323329 cites W1668086213 @default.
• W60323329 cites W1797700808 @default.
• W60323329 cites W1971357899 @default.
• W60323329 cites W1974022382 @default.
• W60323329 cites W1982501876 @default.
• W60323329 cites W1983698019 @default.
• W60323329 cites W1992170852 @default.
• W60323329 cites W1998493448 @default.
• W60323329 cites W2000731858 @default.
• W60323329 cites W2002744434 @default.
• W60323329 cites W2005056727 @default.
• W60323329 cites W2006559495 @default.
• W60323329 cites W2011145513 @default.
• W60323329 cites W2012297570 @default.
• W60323329 cites W2018981978 @default.
• W60323329 cites W2021660402 @default.
• W60323329 cites W2028704745 @default.
• W60323329 cites W2029754521 @default.
• W60323329 cites W2029787353 @default.
• W60323329 cites W2034269086 @default.
• W60323329 cites W2035016947 @default.
• W60323329 cites W2035521247 @default.
• W60323329 cites W2035965301 @default.
• W60323329 cites W2039114426 @default.
• W60323329 cites W2045604110 @default.
• W60323329 cites W2047392226 @default.
• W60323329 cites W2057106513 @default.
• W60323329 cites W2063013559 @default.
• W60323329 cites W2064242629 @default.
• W60323329 cites W2065887259 @default.
• W60323329 cites W2075511135 @default.
• W60323329 cites W2076826746 @default.
• W60323329 cites W2079396676 @default.
• W60323329 cites W2080100938 @default.
• W60323329 cites W2086524655 @default.
• W60323329 cites W2087136249 @default.
• W60323329 cites W2089652792 @default.
• W60323329 cites W2090407808 @default.
• W60323329 cites W2092661658 @default.
• W60323329 cites W2094817491 @default.
• W60323329 cites W2096286606 @default.
• W60323329 cites W2098912234 @default.
• W60323329 cites W2102888099 @default.
• W60323329 cites W2103445331 @default.
• W60323329 cites W2105002879 @default.
• W60323329 cites W2107343029 @default.
• W60323329 cites W2107614388 @default.
• W60323329 cites W2109467838 @default.
• W60323329 cites W2114762453 @default.
• W60323329 cites W2114859236 @default.
• W60323329 cites W2117022661 @default.
• W60323329 cites W2117028091 @default.
• W60323329 cites W2120356140 @default.
• W60323329 cites W2124013343 @default.
• W60323329 cites W2124593509 @default.
• W60323329 cites W2126493366 @default.
• W60323329 cites W2129172946 @default.
• W60323329 cites W2134719928 @default.
• W60323329 cites W2134831715 @default.
• W60323329 cites W2139143163 @default.
• W60323329 cites W2152600551 @default.
• W60323329 cites W2154836325 @default.
• W60323329 cites W2158305336 @default.
• W60323329 cites W2158612356 @default.
• W60323329 cites W2160079255 @default.
• W60323329 cites W2161810908 @default.
• W60323329 cites W2166979725 @default.
• W60323329 cites W4238567307 @default.
• W60323329 cites W4241579353 @default.
• W60323329 cites W4244691161 @default.
• W60323329 doi "https://doi.org/10.1007/82_2010_64" @default.
• W60323329 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20549474" @default.
• W60323329 hasPublicationYear "2010" @default.
• W60323329 type Work @default.
• W60323329 sameAs 60323329 @default.
• W60323329 citedByCount "29" @default.
• W60323329 countsByYear W603233292012 @default.
• W60323329 countsByYear W603233292013 @default.
• W60323329 countsByYear W603233292014 @default.
• W60323329 countsByYear W603233292015 @default.
• W60323329 countsByYear W603233292016 @default.
• W60323329 countsByYear W603233292017 @default.
• W60323329 countsByYear W603233292018 @default.
• W60323329 countsByYear W603233292019 @default.
• W60323329 countsByYear W603233292020 @default.
• W60323329 countsByYear W603233292022 @default.
• W60323329 countsByYear W603233292023 @default.
• W60323329 crossrefType "book-chapter" @default.
• W60323329 hasAuthorship W60323329A5067213450 @default.

• next